105 related articles for article (PubMed ID: 38715180)
21. Plasma levels of TAM receptors and ligands in severe preeclampsia.
Peng S; Sun M; Sun X; Wang X; Jin T; Wang H; Han C; Meng T; Li C
Pregnancy Hypertens; 2018 Jul; 13():116-120. PubMed ID: 30177037
[TBL] [Abstract][Full Text] [Related]
22. TAM family kinases as therapeutic targets at the interface of cancer and immunity.
DeRyckere D; Huelse JM; Earp HS; Graham DK
Nat Rev Clin Oncol; 2023 Nov; 20(11):755-779. PubMed ID: 37667010
[TBL] [Abstract][Full Text] [Related]
23. The TAM Subfamily of Receptor Tyrosine Kinases: The Early Years.
Prieto AL; Lai C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542343
[TBL] [Abstract][Full Text] [Related]
24. Differential regulation of hepatic physiology and injury by the TAM receptors Axl and Mer.
Zagórska A; Través PG; Jiménez-García L; Strickland JD; Oh J; Tapia FJ; Mayoral R; Burrola P; Copple BL; Lemke G
Life Sci Alliance; 2020 Aug; 3(8):. PubMed ID: 32571802
[TBL] [Abstract][Full Text] [Related]
25. Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase.
Kimani SG; Kumar S; Davra V; Chang YJ; Kasikara C; Geng K; Tsou WI; Wang S; Hoque M; Boháč A; Lewis-Antes A; De Lorenzo MS; Kotenko SV; Birge RB
Cell Commun Signal; 2016 Sep; 14(1):19. PubMed ID: 27595981
[TBL] [Abstract][Full Text] [Related]
26. Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells.
Lu Y; Wan J; Yang Z; Lei X; Niu Q; Jiang L; Passtoors WM; Zang A; Fraering PC; Wu F
FASEB J; 2017 Apr; 31(4):1382-1397. PubMed ID: 28034848
[TBL] [Abstract][Full Text] [Related]
27. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
Peeters MJW; Rahbech A; Thor Straten P
Cancer Immunol Immunother; 2020 Feb; 69(2):237-244. PubMed ID: 31664482
[TBL] [Abstract][Full Text] [Related]
28. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
[TBL] [Abstract][Full Text] [Related]
29. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
[TBL] [Abstract][Full Text] [Related]
30. Circulating small extracellular vesicles promote proliferation and migration of vascular smooth muscle cells via AXL and MerTK activation.
Lee YJ; Park M; Kim HY; Kim JK; Kim WK; Lim SC; Kang KW
Acta Pharmacol Sin; 2023 May; 44(5):984-998. PubMed ID: 36450791
[TBL] [Abstract][Full Text] [Related]
31. MERTK tyrosine kinase receptor together with TIM4 phosphatidylserine receptor mediates distinct signal transduction pathways for efferocytosis and cell proliferation.
Nishi C; Yanagihashi Y; Segawa K; Nagata S
J Biol Chem; 2019 May; 294(18):7221-7230. PubMed ID: 30846565
[TBL] [Abstract][Full Text] [Related]
32. TAM receptors in cardiovascular disease.
McShane L; Tabas I; Lemke G; Kurowska-Stolarska M; Maffia P
Cardiovasc Res; 2019 Jul; 115(8):1286-1295. PubMed ID: 30980657
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
Kong D; Tian Q; Chen Z; Zheng H; Stashko MA; Yan D; Earp HS; Frye SV; DeRyckere D; Kireev D; Graham DK; Wang X
J Med Chem; 2024 Apr; 67(7):5866-5882. PubMed ID: 38556760
[TBL] [Abstract][Full Text] [Related]
34.
Saito T; Itoh M; Tohda S
Anticancer Res; 2022 Apr; 42(4):1757-1761. PubMed ID: 35346994
[TBL] [Abstract][Full Text] [Related]
35. TAM receptor tyrosine kinase function and the immunopathology of liver disease.
Mukherjee SK; Wilhelm A; Antoniades CG
Am J Physiol Gastrointest Liver Physiol; 2016 Jun; 310(11):G899-905. PubMed ID: 26867565
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.
Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB
J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939
[TBL] [Abstract][Full Text] [Related]
37. TAM receptors and their ligand-mediated activation: Role in atherosclerosis.
Cai B; Kasikara C
Int Rev Cell Mol Biol; 2020; 357():21-33. PubMed ID: 33234243
[TBL] [Abstract][Full Text] [Related]
38. Antagonistic Coevolution of MER Tyrosine Kinase Expression and Function.
Evans AL; Blackburn JWD; Taruc K; Kipp A; Dirk BS; Hunt NR; Barr SD; Dikeakos JD; Heit B
Mol Biol Evol; 2017 Jul; 34(7):1613-1628. PubMed ID: 28369510
[TBL] [Abstract][Full Text] [Related]
39. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
Front Immunol; 2022; 13():869676. PubMed ID: 35572601
[TBL] [Abstract][Full Text] [Related]
40. TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Dufour F; Silina L; Neyret-Kahn H; Moreno-Vega A; Krucker C; Karboul N; Dorland-Galliot M; Maillé P; Chapeaublanc E; Allory Y; Stransky N; Haegel H; Menguy T; Duong V; Radvanyi F; Bernard-Pierrot I
Br J Cancer; 2019 Mar; 120(5):555-564. PubMed ID: 30765874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
